Roni Burlina

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Lung transplantation (LT) is the standard of care for patients with advanced lung diseases, including lymphangioleiomyomatosis (LAM). LAM accounts for only 1% of all LTs performed in the international registry. As a result, the global experience, including the use of mechanistic target of rapamycin (mTOR) inhibitors before and after LT in LAM, is still(More)
  • 1